KẾT QUẢ ĐIỀU TRỊ BƯỚC HAI PEMBROLIZUMAB UNG THƯ PHỔI KHÔNG TẾ BÀO NHỎ GIAI ĐOẠN IV

Abstract

Objectives: To evaluate the results of the second – line treatment with Pembrolizumab on non small-cell lung cancer stages IV patients at Friendship Hospital and K Hospital. Materials and methods: A cross-sectional, retrospective and prospective study on 34 non small-cell lung cancer stages IV patients who progressed after platinum-based doublet chemotherapy. These patients are treated with Pembrolizumab 2 mg/kg every 3 weeks at Friendship Hospital and K Hospital from January 2018 to December 2021. Results: Mean age of 62,4 ± 8,8 (42-83); male/female ratio = 4,7/1. Lung cancer often metastasizes to contralateral lung, brain and bones. Overall response rate (ORR) is 41,2%, Disease control rate (DCR) is 79,4%. The progression-free survival (PFS) is 12,3 ±1,5 months, (Min: 1,5 months, Max: 25,4 months). Conclusion: The second – line treatment with Pembrolizumab gets a promising response rate, which would be a reasonable option in patients with non-small cell lung cancer stage IV who progressed after platinum-based doublet chemotherapy.